Mirum Pharmaceuticals is trading at $88.00, up 5.68% in pre-market after positive Cohort 2 results from its pivotal PROGRESS study. - Announced October 26, the results were for ATEBRIOZ in children aged 6 to under 12 with FOP. - At 24 weeks, lesion volume decreased with treatment while it increased on placebo; no treated patients developed new lesions. - The company plans to seek an expanded indication in the first half of 2027.